Macrogenics (MGNX) Cash from Financing Activities (2012 - 2026)
Macrogenics' (MGNX) quarterly Cash from Financing Activities came in at -$207000.0 in Q1 2026, up 26.6% year-on-year from -$163512.6 in Q1 2025, and down 463.16% on a QoQ basis from $57000.0 in Q4 2025.
Macrogenics (MGNX) Cash from Financing Activities (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has 15 years of Cash from Financing Activities data on file, last reported at -$207000.0 in Q1 2026.
- On a quarterly basis, Cash from Financing Activities rose 26.6% year-over-year to -$207000.0 in Q1 2026; TTM through Mar 2026 was $69.6 million, a 16083.49% increase from a year earlier, with the FY2025 full-year figure at $69.5 million, up 7141.04% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$207000.0, down from $57000.0 in the prior quarter.
- Over the last five years, Cash from Financing Activities for MGNX reached as high as $100.1 million in Q1 2023 and fell as low as -$282000.0 in Q1 2025.
- Historically, Cash from Financing Activities has averaged $14.8 million across 5 years, with a median of $248000.0 in 2024.
- Across the five-year window, Cash from Financing Activities jumped 270489.19% in 2023 and sank 213.71% in 2025, its largest moves.
- Year by year, Cash from Financing Activities stood at $1.4 million in 2022, then plunged by 79.91% to $273000.0 in 2023, then sank by 43.22% to $155000.0 in 2024, then tumbled by 63.23% to $57000.0 in 2025, then tumbled by 463.16% to -$207000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were -$207000.0 in Q1 2026, $57000.0 in Q4 2025, and $69.7 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Macrogenics | 254.43 Mn | 187.92 Mn | - | -207,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -207,000.00 |
| Mar 31, 2026 | -207,000.00 |
| Dec 31, 2025 | 57,000.00 |
| Dec 31, 2025 | 57,000.00 |
| Jun 30, 2025 | 69.74 Mn |
| Jun 30, 2025 | 69.74 Mn |
| Mar 31, 2025 | -282,000.00 |
| Mar 31, 2025 | -282,000.00 |
| Dec 31, 2024 | 155,000.00 |
| Dec 31, 2024 | 155,000.00 |
| Sep 30, 2024 | -68,000.00 |
| Sep 30, 2024 | -68,000.00 |
| Jun 30, 2024 | 625,000.00 |
| Jun 30, 2024 | 625,000.00 |
| Mar 31, 2024 | 248,000.00 |
| Mar 31, 2024 | 248,000.00 |
| Dec 31, 2023 | 273,000.00 |
| Dec 31, 2023 | 273,000.00 |
| Sep 30, 2023 | 49.91 Mn |
| Sep 30, 2023 | 49.91 Mn |